- Supported exchanges /
- KQ /
- 334970.KQ
Prestige Biologics Co. Ltd. (334970 KQ) stock market data APIs
Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known as PrestigeBio Pharmaceuticals and changed its name to Prestige Biologics Co., Ltd. in October 2019. The company was founded in 2015 and is based in Cheongju-si, South Korea.
Prestige Biologics Co. Ltd. Financial Data Overview
5320 | |
5210 | |
- | |
5320 | |
5100 | |
3850-7830 | |
411 862 M | |
0 | |
2 834 M | |
-103.9521 | |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Prestige Biologics Co. Ltd. Fundamental Data is available in our Financial Data APIs
- Net Revenue 2 834 M
- EBITDA -28 308 330 496
- Earnings Per Share
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get Prestige Biologics Co. Ltd. Earnings via APIs
- Latest Release 2024-09-30
- EPS/Forecast NaN
Get Prestige Biologics Co. Ltd. End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: